Interleukin-6 as a predictor of symptom resolution in psychological distress: A cohort study

Psychological Medicine

Volumn 45, Issue 10, 2015, Pages 2137-2144

  Virtanen, M ^a   Shipley, M J ^b   Batty, G D ^b,c   Hamer, M ^b   Allan, C L ^d   Lowe, G D ^e   Ebmeier, K P ^d   Akbaraly, T N ^b,f,g,h   Alenius, H ^a   Haapakoski, R ^a,b,d   Singh Manoux, A ^b,i   Kivimaki M ^b  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f University of Montpellier   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h UNIV MONTPELLIER   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Anxiety; common mental disorders; cytokines; depression; inflammation; interleukin; recovery

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; BLOOD; CHRONIC DISEASE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS INDICATOR; HUMAN; MALE; MENTAL STRESS; MIDDLE AGED; PSYCHOLOGY; REMISSION; UNITED KINGDOM;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; REMISSION INDUCTION; STRESS, PSYCHOLOGICAL; UNITED KINGDOM;

EID: 84930180545     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715000070     Document Type: Article

References (25)

1. Anderson G, Kubera M, Duda W, Lason W, Berk M, Maes M (2013). Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacological Reports 65, 1647-1654.
2. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM (2013). Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' andlongitudinal 'targets'. Neuropsychopharmacology 38, 377-385.
3. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews. Neuroscience 9, 46-56.
4. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010). A meta-analysis of cytokines in major depression. Biological Psychiatry 67, 446-457.
5. Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, Whooley MA (2011). Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. American Journal of Psychiatry 168, 913-920.
6. Goldberg D,Williams P (1988). AUser's Guide to the General Health Questionnaire. NFER-Nelson Publishing Co.:Windsor, Berkshire.
7. Goldberg DP (1972). The Detection of Psychiatric Illness by Questionnaire. Oxford University Press: London.
8. Hannestad J, DellaGioia N, Bloch M (2011). The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36, 2452-2459.
9. Head J, Stansfeld SA, Ebmeier KP, Geddes JR, Allan CL, Lewis G, Kivimäki M (2013). Use of self-administered instruments to assess psychiatric disorders in older people: validity of the General Health Questionnaire, the Center for Epidemiologic Studies Depression Scale and the self-completion version of the revised Clinical Interview Schedule. Psychological Medicine 43, 2649-2656.
10. Hiles SA, Baker AL, de Malmanche T, Attia J (2012). Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychological Medicine 42, 2015-2026.
11. Howren MB, Lamkin DM, Suls J (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 71, 171-186.
12. Janssen DG, Caniato RN, Verster JC, Baune BT (2010). A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacology 25, 201-215.
13. Kivimaki M, Shipley MJ, Batty GD, Hamer M, Akbaraly TN, Kumari M, Jokela M, Virtanen M, Lowe GD, Ebmeier KP, Brunner EJ, Singh-Manoux A (2014). Long-term inflammation increases risk of common mental disorder: a cohort study. Molecular Psychiatry 19, 149-150.
14. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379.
15. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011). The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Progress in Neuro-Psychopharmacol and Biological Psychiatry 35, 702-721.
16. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65, 732-741.
17. Muller N (2014). Immunology of major depression. Neuroimmunomodulation 21, 123-130.
18. Myint AM, Schwarz MJ, Muller N (2012). The role of the kynurenine metabolism in major depression. Journal of Neural Transmission 119, 245-251.
19. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG (2007). Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. Journal of Psychiatric Research 41, 326-331.
20. Raison CL, Miller AH (2013). The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Molecular Psychiatry 18, 15-37.
21. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II Study. Lancet 373, 2215-2221.
22. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A (1994). Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90, 583-612.
23. Valkanova V, Ebmeier KP, Allan CL (2013). CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. Journal of Affective Disorders 150, 736-744.
24. Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K (2015). Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biological Psychiatry 77, e19-e20.
25. YoshimuraR,HoriH, Ikenouchi-SugitaA,Umene-NakanoW, Ueda N, Nakamura J (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression. Progress inNeuro-PsychopharmacologyandBiological Psychiatry 33, 722-726.